The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy

    January 2022 in “ Journal of Cancer Therapy ”
    Karen López Miguel, Daniel Ricardo Martínez Ávila, Lliset Álvarez Pérez, Gisselle Martínez Rabasa, Alejandro Linchenat Lambert, Roberto Esperón Noa, Lisandra Heredia Manzano, Margarita De Quesada Amigó, Rafael I. Reyes Velázquez, Danay Corrales Otero, Ramón Ropero Toirac, Idelmis Curbelo Heredia, Mircea Betancourt Cabeza, Tania A. Agrelo Ramos, Rosa María Muñoz Reyes, Juan J. Lence Anta, Rosalía Fuentes Sosa, Karelia Silvera Candó, Kirenia Silva Rodríguez, Zaida Lastre Sosa, Mayte Robaina García, Eduardo Sanz, David X. Márquez
    Studysummary In this study, Ocoxin used alongside chemotherapy may improve patients' tolerance to treatment and their quality of life without significant safety concerns, although further research is needed. Our plain-language summary of this paper — not a Tressless recommendation.
    The administration of Ocoxin in patients with advanced epithelial or metastatic ovarian cancer undergoing neoadjuvant chemotherapy significantly improved their quality of life. The study, involving 36 patients, reported a statistically significant increase in the global health status/QoL scale and improvements in symptoms such as fatigue, loss of appetite, and insomnia. Despite the occurrence of 290 adverse events, most were mild or moderate, and only 15 were serious, with none related to Ocoxin. The Karnofsky index improved in 86.1% of patients, indicating better functional status. However, there was a significant decrease in BMI and body weight, highlighting the need for nutritional support during treatment.
    Discuss this study in the Community →